日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting Irgm1 to combat osteoporosis: suppressing ROS and restoring bone remodeling.

靶向 Irgm1 对抗骨质疏松症:抑制 ROS 并恢复骨骼重塑

Cui Zichen, Gu Guanghui, Chen Fei, Li Jianyi, Du Xiaofan, Chen Shuqing, Zhang Han, Li Chenxu, Shao Jiale, Xi Jiayi, Du Yukun, Zhao Qinghua, Xi Yongming

Cost-benefit analysis of p16(INK4a) immunocytology and liquid-based cytology triage after primary HPV testing for cervical cancer screening in China

在中国宫颈癌筛查中,初筛HPV检测后p16(INK4a)免疫细胞学和液基细胞学分流的成本效益分析

Zhou, Dachuang; Hou, Jun; Xi, Jiayi; Li, Yuan; Qu, Xinfeng; Tang, Wenxi; Wu, Ruifang

Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective

对不适合接受含铂方案治疗的非小细胞肺癌患者使用阿特珠单抗的成本效益分析:英国医疗保健视角

Jiang, Yunlin; Zhao, Mingye; Xi, Jiayi; Li, Jiaqi; Tang, Wenxi; Zheng, Xueping